Company intelligence / Profile preview

Orphe

Manassas, Virginia, United Statesorphe.io ↗

Ownership: Private
Development stage: Other

Overview

Orpheus BioScience is developing PR1P, a novel peptide therapeutic that binds and stabilizes VEGF to prevent retinal vascular anomalies in premature neonates with retinopathy of prematurity. PR1P aims to be the first preventative intravenous treatment for ROP, with potential applications in other ocular diseases like diabetic retinopathy and age-related macular degeneration

Therapeutic areas: Ophthalmology
Modalities: Peptides
Industry: Biotech

Beyond the preview

Go deeper on Orphe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orphe.

Explore the full profile